These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 36797599)

  • 1. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis.
    De SK
    Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Characterization of the Topical Soft JAK Inhibitor CEE321 for Atopic Dermatitis.
    Thoma G; Duthaler RO; Waelchli R; Hauchard A; Bruno S; Strittmatter-Keller U; Orjuela Leon A; Viebrock S; Aichholz R; Beltz K; Grove K; Hoque S; Rudewicz PJ; Zerwes HG
    J Med Chem; 2023 Feb; 66(3):2161-2168. PubMed ID: 36657024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abrocitinib for the treatment of atopic dermatitis.
    Crowley EL; Nezamololama N; Papp K; Gooderham MJ
    Expert Rev Clin Immunol; 2020 Oct; 16(10):955-962. PubMed ID: 32969750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
    Saeki H; Akiyama M; Abe M; Igarashi A; Imafuku S; Ohya Y; Katoh N; Kameda H; Kabashima K; Tsunemi Y; Hide M; Ohtsuki M;
    J Dermatol; 2023 Jan; 50(1):e1-e19. PubMed ID: 36412059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
    Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
    Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis.
    Calabrese L; Chiricozzi A; De Simone C; Fossati B; D'Amore A; Peris K
    Expert Opin Drug Metab Toxicol; 2022 May; 18(5):347-355. PubMed ID: 35796377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
    Nakashima C; Yanagihara S; Otsuka A
    Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
    De SK
    Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrocitinib in atopic dermatitis: review of the current literature and clinical trials.
    Napolitano M; Fornaro L; Potestio L; Fabbrocini G; Patruno C
    Drugs Today (Barc); 2022 Aug; 58(8):373-387. PubMed ID: 35983924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of abrocitinib for moderate-to-severe atopic dermatitis.
    Labib A; Yosipovitch G
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1107-1118. PubMed ID: 36173402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abrocitinib: First Approval.
    Deeks ED; Duggan S
    Drugs; 2021 Dec; 81(18):2149-2157. PubMed ID: 34807428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus Kinase Inhibitors in Atopic Dermatitis: New Perspectives.
    Munera-Campos M; Carrascosa JM
    Actas Dermosifiliogr; 2023 Sep; 114(8):680-707. PubMed ID: 37105270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
    Ferreira S; Guttman-Yassky E; Torres T
    Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data.
    Napolitano M; Fabbrocini G; Ruggiero A; Marino V; Nocerino M; Patruno C
    Drug Des Devel Ther; 2021; 15():1135-1147. PubMed ID: 33731985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.
    Nezamololama N; Crowley EL; Gooderham MJ; Papp K
    Expert Opin Investig Drugs; 2020 Sep; 29(9):911-917. PubMed ID: 32741227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
    Roskoski R
    Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delgocitinib: First Approval.
    Dhillon S
    Drugs; 2020 Apr; 80(6):609-615. PubMed ID: 32166597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis.
    Wu J; Li L; Zhu Q; Zhang T; Miao F; Cui Z; Dong G; Tai Z; Chen Z
    Biomed Pharmacother; 2024 Feb; 171():116167. PubMed ID: 38262152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
    Huang IH; Chung WH; Wu PC; Chen CB
    Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.